MarginsXMarginsX
Home › Markets › Health Care › LONA

LeonaBio Inc. (LONA)

LONA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.23
-6.92% on the day
Market cap
$30.4M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLONA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001620463
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
6.3 months
$32.3M cash at June 30, 2026
Share count, 1 year
+138.9%
2025-08-05 to 2026-08-04 · +147.6% over 3 years
Going-concern doubt
No
10-Q filed August 14, 2026
Insider net buying, 12 months
-$93K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Based upon the Company's current operating plan, it estimates that its $ 51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q."
10-Q 2026-08-14
Cash and burn$32.3M cash; operating cash flow -$15.5M a quarter.Report 2026-06-30
Shares outstanding9,421,663 (2026-08-04); 39,439,326 a year earlier; 38,054,583 three years earlier. 1y figure adjusted for split (1-for-10 overall); 3y figure adjusted for split (1-for-10 overall).Cover page 2026-08-04
Reverse splits, 3 years1; latest 1-for-10 on 2025-09-18Source 2025-09-18
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $93K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$19.0M-$17.0M$32.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$32.9M-$20.9M$32.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$82.9M-$19.4M$69.3MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$6.6M-$4.7M$20.9MNo debt tagsNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$7.0M-$7.0M$19.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$9.1M-$14.7M$26.4MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$15.0M-$26.0M$48.4MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$28.7M-$23.0M$68.9MNo debt tagsNeeds four quarters10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-02
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-05-11

Source: SEC EDGAR submissions feed, 472 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-21.4%
1 month-46.0%
3 months-55.9%
Year to date-54.2%
1 year-26.1%
From 52-week high-70.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
CVMCel-Sci Corporation$1.66+29.69%$29.2M
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
ELUTElutia Inc.$0.8229+0.35%$36.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier